- Home
- DIAX vs MYGN Comparison
DIAX vs MYGN Comparison
Compare DIAX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- MYGN
- Stock Information
- Founded
- DIAX 2005
- MYGN 1991
- Country
- DIAX United States
- MYGN United States
- Employees
- DIAX N/A
- MYGN N/A
- Industry
- DIAX Finance Companies
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DIAX Finance
- MYGN Health Care
- Exchange
- DIAX Nasdaq
- MYGN Nasdaq
- Market Cap
- DIAX 521.1M
- MYGN 423.1M
- IPO Year
- DIAX N/A
- MYGN 1995
- Fundamental
- Price
- DIAX $14.72
- MYGN $6.61
- Analyst Decision
- DIAX
- MYGN Hold
- Analyst Count
- DIAX 0
- MYGN 13
- Target Price
- DIAX N/A
- MYGN $13.50
- AVG Volume (30 Days)
- DIAX 96.6K
- MYGN 1.5M
- Earning Date
- DIAX 01-01-0001
- MYGN 11-06-2025
- Dividend Yield
- DIAX 7.93%
- MYGN N/A
- EPS Growth
- DIAX N/A
- MYGN N/A
- EPS
- DIAX N/A
- MYGN N/A
- Revenue
- DIAX N/A
- MYGN $832,900,000.00
- Revenue This Year
- DIAX N/A
- MYGN $0.17
- Revenue Next Year
- DIAX N/A
- MYGN $6.19
- P/E Ratio
- DIAX N/A
- MYGN N/A
- Revenue Growth
- DIAX N/A
- MYGN 3.83
- 52 Week Low
- DIAX $12.80
- MYGN $3.76
- 52 Week High
- DIAX $15.12
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- DIAX 64.07
- MYGN 64.60
- Support Level
- DIAX $14.60
- MYGN $5.78
- Resistance Level
- DIAX $14.80
- MYGN $7.05
- Average True Range (ATR)
- DIAX 0.11
- MYGN 0.34
- MACD
- DIAX 0.01
- MYGN 0.07
- Stochastic Oscillator
- DIAX 75.68
- MYGN 75.82
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.